ANDA 207329, held by Chartwell Rx. Oxybutynin Chloride.
As of Nov 15, 2026, ANDA 207329 (Oxybutynin Chloride), held by Chartwell Rx, was first approved by FDA on May 31, 2018, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 31, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Oxybutynin Chloride10% (100MG/PACKET) ยท gel;transdermal | Oxybutynin Chloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
